{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:34Z","timestamp":1792670854219,"version":"4.5.0"},"reference-count":41,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"unspecified","delay-in-days":94,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>Invasive meningococcal disease has high morbidity and mortality, with infants and young children among those at greatest risk. This phase III, open-label, randomised study in toddlers aged 12\u201323 months evaluated the immunogenicity and safety of meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT), a tetanus toxoid conjugated vaccine against meningococcal serogroups A, C, W and Y, when coadministered with paediatric vaccines (measles, mumps and rubella [MMR]; varicella [V]; 6-in-1 combination vaccine against diphtheria, tetanus, pertussis, polio, hepatitis B and <jats:italic>Haemophilus influenzae<\/jats:italic> type b [DTaP-IPV-HepB-Hib] and pneumococcal conjugate vaccine [PCV13])(NCT03205371). Immunogenicity to each meningococcal serogroup was assessed by serum bactericidal antibody assay using human complement (hSBA). Vaccine safety profiles were described up to 30 days post-vaccination. A total of 1183 participants were enrolled. The proportion with seroprotection (hSBA \u22651:8) to each meningococcal serogroup at Day 30 was comparable between the MenACYW-TT and MenACYW-TT + MMR + V groups (\u226592 and \u226596%, respectively), between the MenACYW-TT and MenACYW-TT + DTaP-IPV-HepB-Hib groups (\u226590% for both) and between the MenACYW-TT and MenACYW-TT + PCV13 groups (\u226591 and \u226584%, respectively). The safety profiles of MenACYW-TT, and MMR + V, DTaP-IPV-HepB-Hib, and PCV13, with or without MenACYW-TT, were generally comparable. Coadministration of MenACYW-TT with paediatric vaccines in toddlers had no clinically relevant effect on the immunogenicity and safety of any of the vaccines.<\/jats:p>","DOI":"10.1017\/s0950268821000698","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T08:55:46Z","timestamp":1617612946000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":20,"title":["Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study"],"prefix":"10.1017","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-7165","authenticated-orcid":false,"given":"M. S.","family":"Dhingra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Namazova-Baranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Arredondo-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Limkittikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Jantarabenjakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Perminova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A. R.","family":"Kobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-W.","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chansinghakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"B'Chir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neveu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonaparte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jordanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"S0950268821000698_ref13","first-page":"E454","article-title":"Rise in invasive serogroup W meningococcal disease in Australia 2013\u20132015","volume":"40","author":"Martin","year":"2016","journal-title":"Communicable Diseases Intelligence Quarterly Report"},{"key":"S0950268821000698_ref27","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318268dfe4"},{"key":"S0950268821000698_ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0213-2"},{"key":"S0950268821000698_ref36","first-page":"1825","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix\u2122): a review of its immunogenicity, safety, co-administration, and antibody persistence","volume":"12","author":"Assaf-Casals","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"S0950268821000698_ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-018-1440-z"},{"key":"S0950268821000698_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16725-1"},{"key":"S0950268821000698_ref3","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1557520"},{"key":"S0950268821000698_ref26","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.4.2.156-167.1997"},{"key":"S0950268821000698_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(86)90048-0"},{"key":"S0950268821000698_ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0254-1"},{"key":"S0950268821000698_ref15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1091908"},{"key":"S0950268821000698_ref10","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1532248"},{"key":"S0950268821000698_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.04.067"},{"key":"S0950268821000698_ref32","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890320310"},{"key":"S0950268821000698_ref11","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245"},{"key":"S0950268821000698_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.078"},{"key":"S0950268821000698_ref28","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318212eb80"},{"key":"S0950268821000698_ref17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733867"},{"key":"S0950268821000698_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(91)90266-9"},{"key":"S0950268821000698_ref19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733868"},{"key":"S0950268821000698_ref39","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268816000704"},{"key":"S0950268821000698_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.013"},{"key":"S0950268821000698_ref8","unstructured":"8. European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. Available at https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet."},{"key":"S0950268821000698_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.062"},{"key":"S0950268821000698_ref41","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-11-17"},{"key":"S0950268821000698_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.017"},{"key":"S0950268821000698_ref6","unstructured":"6. European Centre for Disease Prevention and Control. Invasive meningococcal disease: Annual Epidemiological Report for 2017. Available at https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf."},{"key":"S0950268821000698_ref23","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000261"},{"key":"S0950268821000698_ref18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733869"},{"key":"S0950268821000698_ref30","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199608000-00010"},{"key":"S0950268821000698_ref12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1051276"},{"key":"S0950268821000698_ref1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1258308"},{"key":"S0950268821000698_ref25","unstructured":"25. World Health Organization, WHO vaccine-preventable diseases: monitoring system. 2020 global summary. Available at https:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/diseases. Accessed 15 October 2020."},{"key":"S0950268821000698_ref35","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000930"},{"key":"S0950268821000698_ref5","unstructured":"5. Centers for Disease Control and Prevention. (2017) Enhanced Meningococcal Disease Surveillance Report. Available at https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2017.pdf."},{"key":"S0950268821000698_ref22","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002832"},{"key":"S0950268821000698_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.05.006"},{"key":"S0950268821000698_ref34","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1521280"},{"key":"S0950268821000698_ref9","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v45i06a04"},{"key":"S0950268821000698_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.013"},{"key":"S0950268821000698_ref29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.5.810"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268821000698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T11:37:35Z","timestamp":1619005055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268821000698\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":41,"alternative-id":["S0950268821000698"],"URL":"https:\/\/doi.org\/10.1017\/s0950268821000698","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2021. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is included and the original work is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e90"}}